Gracell Biotechnologies Stock News

The FDA granted Orphan Drug Designation for Gracell Biotechnologies Inc''s (NASDAQ: GRCL ) GC012F, FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T cell therapy for multiple myeloma. The long-term follow-up data for GC012F was Full story available on Benzinga.com

(RTTNews) - Clinical-stage biopharmaceutical company Gracell Biotechnologies Inc. (GRCL) announced the FDA has granted Orphan Drug Designation for GC012F, the company''s FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T cell therapy for the treatment of multiple myeloma. GC012F is currently being evaluated in investigator-initiated phase 1 trials in

SUZHOU, China and PALO ALTO, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (Gracell), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 th to December 2 nd .

Gracell Biotechnologies (NASDAQ:GRCL) posted its earnings results on Sunday. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts consensus estimates of ($0.12) by ($0.18), Fidelity Earnings reports. GRCL traded up $0.36 on Tuesday, reaching $11.28. The stock had a trading volume of 113,251 shares, compared to its average volume of 119,267. []

Gracell Biotechnologies (NASDAQ:GRCL) released its quarterly earnings results on Monday. The company reported ($0.30) earnings per share for the quarter, missing the Zacks consensus estimate of ($0.12) by ($0.18), Fidelity Earnings reports. NASDAQ GRCL traded up $0.15 during trading hours on Tuesday, reaching $11.07. 414 shares of the company traded hands, compared to its average []

SUZHOU, China and PALO ALTO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (Gracell), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today reported its unaudited financial results for the third quarter of the year and provided recent business highlights.

SUZHOU, China and PALO ALTO, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to disco

SUZHOU, China and PALO ALTO, Calif., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to disco

SUZHOU, China and PALO ALTO, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to disco

Gracell Biotechnologies, Inc. (GRCL) CEO William Wei Cao on Q2 2021 Results - Earnings Call Transcript

SUZHOU, China and PALO ALTO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to disco

SUZHOU, China and PALO ALTO, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to disco

SUZHOU, China and PALO ALTO, Calif., May 26, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering an

SUZHOU, China and PALO ALTO, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discov